Inventor

BROWNING JEFFREY L

US23 patents

⚠️ This page may combine multiple inventors who share the name “BROWNING JEFFREY L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BROWNING JEFFREY L

BIOGEN IDEC INC

Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents

Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosus

Receptor coupling agents and compositions thereof

Methods of promoting neurite outgrowth with soluble TAJ polypeptides

Anti-lymphotoxin-β receptor antibodies as anti-tumor agents

Methods for inhibiting lymphotoxin β receptor signalling

Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents

Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

BIOGEN INC

Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease

Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease

Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases

DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V &amp; VI

DNA sequences recombinant DNA molecules and processes for producing lipocortins III, IV, V and VI

BROWNING JEFFREY L

Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins

Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor

(unassigned)

Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents

UNIV NEW YORK

Treatment of follicular lymphomas using inhibitors of the LT pathway

BECKMAN EVAN

Compositions comprising variant LT-B-R-IG fusion proteins

DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI